Madrigal Pharmaceuticals (NASDAQ: MDGL) reshapes Board classes ahead of 2026 meeting
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Madrigal Pharmaceuticals, Inc. reported a change in how its Board of Directors is classified, without changing who serves on the Board. On April 22, 2026, the Board rebalanced the membership of its three director classes so each class will be as evenly sized as possible after the 2026 Annual Meeting of Stockholders on June 17, 2026.
To accomplish this, Julian C. Baker and Daniel J. Brennan were reclassified as Class I directors, whose terms expire at the 2026 Annual Meeting. Each resigned from his prior Class III and Class II seat, respectively, solely to allow simultaneous reappointment as a Class I director, and their Board service is considered uninterrupted. Their committee assignments did not change, and both, along with James Daly, have been nominated for re-election at the 2026 Annual Meeting.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Board reclassification date: April 22, 2026
2026 Annual Meeting date: June 17, 2026
Proxy filing date: April 28, 2026
+1 more
4 metrics
Board reclassification date
April 22, 2026
Effective date when the Board reclassified director classes
2026 Annual Meeting date
June 17, 2026
Date of Madrigal’s 2026 Annual Meeting of Stockholders
Proxy filing date
April 28, 2026
Date the Definitive Proxy Statement was filed
Director class terms
Class I: 2026, Class II: 2027, Class III: 2028
Stated expiration years for each Board class’s term
Key Terms
Class I director, Annual Meeting of Stockholders, Definitive Proxy Statement, Board of Directors
4 terms
Class I director regulatory
"should be reclassified to Class I (with a term expiring at the 2026 Annual Meeting). Accordingly, effective April 22, 2026, Julian C. Baker and Daniel J. Brennan have been reclassified as Class I directors"
A class I director is a member of a company’s board who belongs to one of several groups whose terms expire in a specified year under a staggered election system; each class is elected on a different cycle so only a portion of the board faces re-election each year. This matters to investors because it affects how quickly control of the board can change, the company’s continuity and oversight, and the ease of mounting or defending against takeover efforts—think of a team where only some players are replaced each season rather than the whole roster at once.
Annual Meeting of Stockholders regulatory
"following its Annual Meeting of Stockholders to be held on June 17, 2026 (the "2026 Annual Meeting")"
Definitive Proxy Statement regulatory
"As disclosed in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 28, 2026"
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
Board of Directors regulatory
"the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”) completed a process to reclassify the membership of the Board’s three classes of directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
FAQ
What Board change did Madrigal Pharmaceuticals (MDGL) report in this 8-K?
Madrigal Pharmaceuticals reported a reclassification of its Board of Directors into three more evenly sized classes. Two existing directors shifted into Class I, but remained on the Board with uninterrupted service and unchanged committee assignments.
Which Madrigal Pharmaceuticals directors were reclassified and into which class?
Julian C. Baker and Daniel J. Brennan were reclassified as Class I directors. Baker moved from Class III and Brennan from Class II, with their prior resignations conditioned on simultaneous reappointment to Class I.
Why did Madrigal Pharmaceuticals reclassify its Board director classes?
The Board reclassified director classes to achieve a more equal apportionment of membership among its three classes. This adjustment is intended to balance the number of directors in each class following the company’s 2026 Annual Meeting of Stockholders.
Did the reclassification affect Madrigal Pharmaceuticals directors’ committee assignments?
The company stated there were no changes to Julian C. Baker’s or Daniel J. Brennan’s committee assignments as a result of the reclassification. Only their class designation on the Board changed, while their Board responsibilities otherwise remained the same.
Whose terms will expire at Madrigal Pharmaceuticals’ 2026 Annual Meeting?
Class I directors’ terms will expire at the 2026 Annual Meeting of Stockholders. After the reclassification, this includes Julian C. Baker and Daniel J. Brennan, who were moved into Class I with terms ending at that 2026 meeting.
Who has been nominated for re-election at Madrigal Pharmaceuticals’ 2026 Annual Meeting?
The company disclosed that Julian C. Baker, Daniel J. Brennan, and James Daly have been nominated to stand for re-election at the 2026 Annual Meeting, as described in its Definitive Proxy Statement filed on April 28, 2026.